L'intérêt à découvert pour Conduit Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Conduit Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Rapport sur les intérêts à découvert

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

News

Camden Property Trust Reports Minor Damage From Hurricanes Helene And Milton, Will Provide Updates If Material Changes Occur

UMH Properties Reports Minimal Impact From Hurricane Milton, No Material Effect On Operations Or Financial Results

Insider Trades

ALVR

Octagon Capital Advisors Reports 9.7% Passive Stake In AlloVir

Looking into the current session, Permian Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>) shares are trading at $14.52, after a 0.83% spike. Moreover, over the past month, the stock spiked by 7.64%, but in the past year, fell by 3.39%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1728677757_0.png" alt="Past Year Chart" />

<h3>Comparing Permian Resources P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Permian Resources has a lower P/E than the aggregate P/E of 18.07 of the Oil, Gas &amp; Consumable Fuels industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1728677757_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Permian Resources

The S&amp;P 500 and Dow Jones Industrial Average <a href="https://www.benzinga.com/news/earnings/24/10/41293799/s-p-500-dow-jones-hit-new-record-highs-as-financial-stocks-soar-on-upbeat-earnings">both achieved record highs</a> this week.
A strong kickoff to the third-quarter earnings season fueled both indexes, offsetting concerns from last <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41270761/september-inflation-hotter-than-expected-jobless-claims-spike-the-most-in-over-a-">month's unexpected inflation surge.</a>
JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of New York Mellon Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) and BlackRock Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) all exceeded analyst earnings forecasts Friday. This triggered a stock rally and propelled the financial <a href="https://www.benzinga.com/news/earnings/24/10/41293190/us-banks-top-q3-earnings-estimates-jpmorgan-delivers-robust-beat-financial-sector-stocks-hit-record">sector to new highs.</a>
In contrast, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) faced investor disappointment. The Austin, Texas-based car company is one of the worst performers within the S&amp;P 500 this week.
The much-anticipated "We, Robot" event on Thursday was partly to blame. The presentation failed to impress analysts and investors, alike. Critics said it was <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41295072/tesla-robotaxi-day-event-more-fanfare-than-substance-8-analysts-on-cybercab-optimus">more fanfare than substance</a>. 
While the company showcased its CyberCab and Optimus robot, key details about commercialization and timelines were lacking. The event sparked mixed reactions from investors, with concerns about whether Tesla can deliver on its ambitious autonomous vehicle promises.
As a result, the Elon Musk-led EV manufacturer saw its <a href="https://www.benzinga.com/markets/equities/24/10/41289653/tesla-stock-poised-to-pullback-to-1-month-low-whats-going-on">share price plunge Friday</a>. 
You might have missed…
<h3 class="wp-block-heading">Economic data disappoints</h3>
September inflation reports for both <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41270761/september-inflation-hotter-than-expected-jobless-claims-spike-the-most-in-over-a-">consumers</a> and <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41290382/producer-inflation-rises-more-than-expected-in-september-as-food-transportation-c">producers</a> come in higher than expected, while jobless claims posted the sharpest rise in over a year.
Despite the inflation uptick, interest rate expectations remained largely unchanged, with most traders and economists maintaining their outlook for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">a November rate cut</a>. The unemployment spike was attributed to temporary factors, including Michigan auto layoffs and Hurricane Helene.
<h3 class="wp-block-heading">No Stimulus Measures In China</h3>
Chinese stocks saw their worst weekly performance of the year. The absence of expected stimulus measures from Chinese authorities weighed heavily on investor sentiment, despite a strong rally in recent weeks.
<h3 class="wp-block-heading">Mortgage Rates Surge</h3>
Mortgage rates saw a sharp reversal last week, jumping to 6.36% and leading to a 5.1% drop in homebuyer applications. The housing market awaits further rate cuts, but rising Treasury yields —driven by a resilient labor market — pose significant challenges to mortgage rate relief <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41249628/mortgage-rates-make-dramatic-u-turn-freezing-homebuyers-applications-fall-5-as-ma">in the near term.</a>
<h3 class="wp-block-heading">Google fights back</h3>
Alphabet Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google is challenging the Department of Justice&#8217;s efforts to break up its search dominance, labeling the proposed <a href="https://www.benzinga.com/markets/equities/24/10/41244481/google-cries-foul-as-doj-moves-to-break-up-search-giant-calls-recommendations-radical-as-antitru">antitrust remedies as radical.</a> 
The tech giant argues the DOJ's recommendations could dismantle its core business, impacting innovation and consumer choice.
Keep Reading:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41281645/18-stocks-to-buy-7-to-sell-this-earnings-season-goldman-sachs-calls-it-the-year-of-">18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It &#8216;The Year Of The Stock Picker&#8217;</a></li>
</ul>

Earnings

Equities

Econ #s

Economics

GOOGL

TSLA

Wall Street Marks New Record Highs On Strong Start To Earnings Season, Investors Downplay Inflation Surge, Tesla Disappoints: This Week In The Market

MAPS

WM Technology Got Notice Of Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq

Financing

AMCX

Millennium Management Reports 5.7% Passive Stake In AMC Networks

At September 30, 2024, Peabody has completed approximately $250 million of the anticipated $489 million of initial development capital to achieve longwall production in March 2026. With a $210 per metric ton benchmark price assumption, Centurion has an estimated net present value of $1.6 billion and a 25 percent internal rate of return.
"Peabody is committed to increasing shareholder value through a balanced approach of maximizing shareholder returns and developing Centurion," Mark Spurbeck, Peabody's Chief Financial Officer, said. "Centurion provides increased optionality to tightening metallurgical coal markets and will be a strategic asset in Peabody's global coal portfolio for decades."

Peabody Provides Update On Centurion Metallurgical Coal Mine Development; Integrated Mine Plan Complete With Estimated Net Present Value Of $1.6B; Average Annual Production Of 4.7M Tons At First Quartile Cost And Mine Life Of 25+ Years

At the recent <a href="https://www.benzinga.com/events/">Benzinga Cannabis Capital Conference</a> in Chicago (Oct. 8 and 9), Emily Paxhia, founding partner and managing partner of Poseidon Investment Management, shared her thoughts on one of the most pressing legal battles facing the cannabis industry. 
Speaking shortly after her panel, <a href="https://www.linkedin.com/feed/update/urn:li:activity:7249927868892286976">Paxhia discussed</a> a Supreme Court case that could have a transformative impact on how cannabis businesses operate within legal states, offering the industry a potential pathway to freedom from federal interference.
<h1 class="wp-block-heading">Supreme Court Battle</h1>
During the interview, Paxhia emphasized the importance of a Supreme Court case she is pursuing with David Boies, a renowned constitutional lawyer. This case could reshape the federal government's involvement in state-legal cannabis businesses. 
"I would love it if we could get more industry support around this case because it would define boundaries around our businesses that would let them run without the federal government&#8217;s overreach," said Paxhia. 
The case challenges a 2005 ruling on the Commerce Clause, which Paxhia believes is outdated. She explained the significance of the case: "All we're asking for is for the federal government to recognize that the industry exists within certain states, legal states, with programs, and that it would mean that the CSA [Controlled Substances Act] does not empower the DOJ [U.S. Department of Justice] to interfere with those businesses."
If successful, this case could lead to major changes for cannabis businesses. It could open up opportunities for banking access, insurance providers and credit card services — options that are currently denied to many cannabis operators. 
Paxhia pointed out, "It would create opportunities for us to have banking access, insurance providers, credit cards, all of the things that other businesses enjoy that we are simply deprived of."
<h1 class="wp-block-heading">The Burden of Federal Tax Code 280E</h1>
Paxhia also touched on the ongoing challenges that cannabis businesses face due to the federal tax code 280E, which prevents them from deducting ordinary business expenses. This has resulted in an effective tax rate of around 70% for many companies in the industry. 
She advised companies to remain financially cautious: "We are advising our companies to run lean and be very careful. We talk a lot about SG&amp;A containment and being prudent about the efficiencies of the operations."
Though there is hope that rescheduling cannabis could eliminate 280E, Paxhia noted that this is not an immediate solution. She highlighted that the case she is involved in could lead to retroactive refunds for cannabis businesses if the ruling is favorable: "This case would create a look back where you would be able to get a refund for prior years of 280E."
With a Supreme Court case on the horizon and the ongoing burden of 280E, Paxhia's message was clear: the cannabis industry needs to continue its fight for legal recognition while remaining financially prudent to navigate the existing challenges.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Don't miss your chance to be part of Cannabis Market Spotlight: California in Anaheim on Nov. 12. Whether you're looking to connect with industry leaders, explore investment opportunities, or gain the latest insights into California's cannabis market, this event has it all. <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Secure your spot today!</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Photo: Shutterstock

Cannabis

Government

Regulations

Legal

Events

Exclusives

Interview

Federal Overreach Vs. State Rights: Can Cannabis Businesses Gain Independence?

A2Z Cust2Mate Solutions Corp. (the "Company" or "A2Z") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZ#NASDAQ">AZ</a>), a global leader in innovative technology solutions, today announced that it has entered into a definitive securities purchase agreement with certain accredited investors to issue, in a registered direct offering, up to 642,860 common shares at a purchase price of US$2.80 per share. Subject to customary closing conditions, the transaction is expected to close on or around Tuesday, October 15, 2024. A2Z anticipates that the net proceeds from this offering, after deducting offering expenses, will be used for working capital and general corporate purposes. No placement agent was used or participated in the offering.

Offerings

A2Z Cust2Mate Solutions Announces Aggregate $1.8M Registered Direct Offering Of 642,860 Common Shares Priced At $2.80/Share, With No Warrants

FCPT

FCPT Announces Acquisition Of Tires Plus Property In Georgia For $2.1M Under Long-Term Triple Net Lease

China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) reported quarterly losses of $(2.04) per share. This is a 1233.33 percent decrease over earnings of $0.18 per share from the same period last year. The company reported $890.00 thousand in sales this quarter. This is a 34.56 percent decrease over sales of $1.36 million the same period last year.

CLEU

China Liberal Education H1 EPS $(2.04) Down From $0.18 YoY, Sales $890.00K Down From $1.36M YoY

<a href="https://x.com/IranIntl_En/status/1844812179826212963">https://x.com/IranIntl_En/status/1844812179826212963</a>
"Nearly all three branches of Iran's government - the judiciary, the legislature and the executive branch - have been hit by heavy cyberattacks, and their information stolen," said Firouzabadi, the ex-secretary of Iran's Supreme Council of Cyberspace, without explaining when those attacks happened.&nbsp;
"Our nuclear facilities have also been targeted by cyberattacks, as well as networks like fuel distribution, municipal networks, transportation networks, ports, and similar sectors. These are just part of a long list of various areas across the country that have been attacked."

Macro Economic Events

Global

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Iran International English Posts On X ""Nearly all three branches of Iran's government - the judiciary, the legislature and the executive branch - have been hit by heavy cyberattacks, and their information stolen," said Firouzabadi, the ex-secretary of Iran's Supreme Council of Cyberspace, without explaining when those attacks happened...."

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock&#39;s price. Do they really matter, though?
Let&#39;s take a look at what these Wall Street heavyweights have to say about TJX (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tjx#NYSE">TJX</a>) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.
TJX currently has an average brokerage recommendation of 1.24, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 25 brokerage firms. An ABR of 1.24 approximates between Strong Buy and Buy.
Of the 25 recommendations that derive the current ABR, 22 are Strong Buy, representing 88% of all recommendations.
<h2>Brokerage Recommendation Trends for TJX</h2>
<img alt="Broker Rating Breakdown Chart for TJX" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/TJX_10112024.png" style="width:100%" title="" /> 
The ABR suggests buying TJX, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every &quot;Strong Sell&quot; recommendation, brokerage firms assign five &quot;Strong Buy&quot; recommendations.
In other words, their interests aren&#39;t always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock&#39;s price movement.
With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock&#39;s near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.
<h2>ABR Should Not Be Confused With Zacks Rank</h2>
In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers&#39; vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.
In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.
<h2>Should You Invest in TJX?</h2>
Looking at the earnings estimate revisions for TJX, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.15.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for TJX.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for TJX.
<a href="https://www.zacks.com/stock/news/2349272/is-it-worth-investing-in-tjx-tjx-based-on-wall-street-s-bullish-views?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2349272">To read this article on Zacks.com click here.</a>

Large Cap

Analyst Ratings

Trading Ideas

Is It Worth Investing in TJX Based on Wall Street's Bullish Views?

VLDX

Velo3D Inc Commences Workforce Reduction Impacting 46 Employees Globally

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock&#39;s price. Do they really matter, though?
Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let&#39;s see what these Wall Street heavyweights think about ServiceNow (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/now#NYSE">NOW</a>).
ServiceNow currently has an average brokerage recommendation&nbsp;of 1.29, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 34 brokerage firms. An ABR of 1.29 approximates between Strong Buy and Buy.
Of the 34 recommendations that derive the current ABR, 29 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 85.3% and 5.9% of all recommendations.
<h2>Brokerage Recommendation Trends for NOW</h2>
<img alt="Broker Rating Breakdown Chart for NOW" class="chart" src="https://staticx-tuner.zacks.com/images/yesopchart/brokerage_bar/NOW_10112024.png" style="width:100%" title="" /> 
While the ABR calls for buying ServiceNow, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.
Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every &quot;Strong Sell&quot; recommendation, brokerage firms assign five &quot;Strong Buy&quot; recommendations.
This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock&#39;s future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.
Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock&#39;s price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.
<h2>ABR Should Not Be Confused With Zacks Rank</h2>
Although both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.
The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.
Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.
On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.
Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company&#39;s changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.
<h2>Is NOW a Good Investment?</h2>
Looking at the earnings estimate revisions for ServiceNow, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $13.75.
Analysts&#39; steady views regarding the company&#39;s earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.
The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for ServiceNow.
It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for ServiceNow.
<a href="https://www.zacks.com/stock/news/2349270/is-servicenow-now-a-buy-as-wall-street-analysts-look-optimistic?cid=CS-BENZ-FT-fundamental_analysis|average_broker_rating-2349270">To read this article on Zacks.com click here.</a>

Tech

Is ServiceNow a Buy as Wall Street Analysts Look Optimistic?

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) has outperformed the market over the past 5 years by 32.37% on an annualized basis producing an average annual return of 46.55%. Currently, Capricor Therapeutics has a market capitalization of $616.28 million. 
Buying $1000 In CAPR: If an investor had bought $1000 of CAPR stock 5 years ago, it would be worth $6,785.99 today based on a price of $17.44 for CAPR at the time of writing.
<h3>Capricor Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728677024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today

Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 5.96% on an annualized basis producing an average annual return of 20.14%. Currently, Goldman Sachs Gr has a market capitalization of $163.24 billion. 
Buying $1000 In GS: If an investor had bought $1000 of GS stock 5 years ago, it would be worth $2,510.49 today based on a price of $516.92 for GS at the time of writing.
<h3>Goldman Sachs Gr's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728677020_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Hingham Institution (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIFS#NASDAQ">HIFS</a>) reported quarterly earnings of $1.44 per share. This is a 9.09 percent increase over earnings of $1.32 per share from the same period last year. The company reported $11.26 million in sales this quarter. This is a 4.28 percent decrease over sales of $11.76 million the same period last year.

HIFS

Hingham Institution Q3 Adj $1.44 Up From $1.32 YoY, Sales $11.26M Down From $11.76M YoY

WIIM

NRIX

Nurix Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!



Moving stocks are new agreements, a patent, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SILO Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock is rocketing more than 69% after <a href="https://www.nasdaq.com/press-release/silo-pharma-secures-exclusive-global-license-alzheimers-therapeutic-2024-07-16">securing a new license</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) shares are soaring over 65% with heavy pre-market trading.</li>



<li>SciSparc (NASDAQ:<a href="https://investorplace.com/stock-quotes/sprc-stock-quote/">SPRC</a>) stock is surging more than 39% on a <a href="https://www.nasdaq.com/press-release/scisparc-announces-us-patent-application-treating-metabolic-syndrome-and-weight-loss">new weight loss patent</a>.</li>



<li>Meiwu Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/wnw-stock-quote/">WNW</a>) shares are rising over 30% with strong early morning trading.</li>



<li>Singing Machine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mics-stock-quote/">MICS</a>) stock is increasing more than 25% on a <a href="https://www.nasdaq.com/press-release/singing-machines-subsidiary-semicab-announces-over-9-million-contracted-revenue">$9 million revenue backlog contract</a>.</li>



<li>Passage Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pasg-stock-quote/">PASG</a>) shares are gaining over 18% on <a href="https://www.nasdaq.com/press-release/passage-bio-announces-positive-feedback-fda-expansion-uplift-d-trial-pbft02-include">clinical trial expansion feedback</a>.</li>



<li>AEON Biopharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aeon-stock-quote/">AEON</a>) stock is climbing more than 16% with strong pre-market trading.</li>



<li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) shares are getting an over 12% boost after <a href="https://www.stocktitan.net/news/SISI/shineco-announces-closing-of-2-million-underwritten-public-r9iot7ulzqfp.html">closing a public offering</a>.</li>



<li>SMX (Security Matters) (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/">SMX</a>) stock is jumping more than 11% <a href="https://www.nasdaq.com/press-release/smx-announces-effective-date-reverse-stock-split-2024-07-11">following a reverse stock split</a>.</li>



<li>Biomerica (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmra-stock-quote/">BMRA</a>) shares are up over 11% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Autonomix Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock is diving more than 18% <a href="https://www.nasdaq.com/press-release/autonomix-enters-definitive-agreement-license-intellectual-property-fda-cleared">following a rally yesterday</a>.</li>



<li>Vince (NYSE:<a href="https://investorplace.com/stock-quotes/vnce-stock-quote/">VNCE</a>) shares are tumbling over 17% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is taking a more than 17% beating on Tuesday morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are sliding over 17% after <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">rising yesterday on a strategic alliance</a>.</li>



<li>Lottery.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltry-stock-quote/">LTRY</a>) stock is dropping more than 16% on Tuesday.</li>



<li>Vicinity Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) shares are decreasing over 16% this morning.</li>



<li>Tantech (NASDAQ:<a href="https://investorplace.com/stock-quotes/tanh-stock-quote/">TANH</a>) stock is falling more than 15% despite a lack of news this morning.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are slipping over 14% on Tuesday morning.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is dropping close to 14% <a href="https://www.benzinga.com/news/24/07/39781479/cyngn-shares-were-up-by-more-than-50-whats-going-on">after a recent rally</a>.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is taking off on Tuesday alongside <a href="https://finance.yahoo.com/news/conduit-pharmaceuticals-receives-patent-approval-113000596.html">a new patent</a> for the clinical-stage specialty biopharmaceutical company.



Conduit Pharmaceuticals notes that it now has an Austrailian patent that covers its HK-4 Glucokinase Activator that targets autoimmune diseases. That&rsquo;s a highlight for CDT stock as this is the company&rsquo;s lead asset.



Conduit Pharmaceuticals also notes that this approval leads it to believe that it could get similar patents in other regions. The company plans to use the Patent Prosecution Highway (PPHH to seek approval in the U.S., Europe and Japan.



Conduit Pharmaceuticals CEO Dr. David Tapolczay said the following about the news.




&ldquo;The approval of the composition of matter patent in Australia for our lead asset augments our commitment to optimizing the value of our intellectual property portfolio. With up to 20 years of patent protection and drug substance classification secured, this patent not only validates the robustness of our internal R&amp;D capabilities but also significantly strengthen our position for future out-licensing opportunities.&rdquo;




<h2>How This Affects CDT Stock Today</h2>



With this news comes heavy trading of CDT shares on Tuesday. That has more than 41.7 million shares changing hands as of this writing. This is well above its daily average trading volume of about 317,000 units.



CDT stock is up 73% as of Tuesday morning. However, shares were down 94.9% year-to-date when markets closed yesterday.



There are plenty of other stock market stories traders will want to read about on Tuesday!



Fortunately, we have all of that ready to go with our market coverage today! Among that is what has shares of Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock up, the biggest pre-market stock movers this morning and more. All of this info is ready at the following links!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Tuesday</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-rumble-rum-stock-call-options-as-trump-trades-gain/">Trade of the Day: Buy Rumble (RUM) Stock Call Options as Trump Trades Gain</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Autonomix Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock is taking a beating on Tuesday after the development stage medical device company saw its shares undergo a rally yesterday.



That came as it provided updates on its <a href="https://finance.yahoo.com/news/autonomixs-trial-results-show-meaningful-173000465.html">pancreatic cancer pain management device</a>. This includes positive results from a clinical trial covering its device. This uses radiofrequency (<a href="https://investorplace.com/stock-quotes/rf-stock-quote/">RF</a>) ablation to reduce the pain of patients with pancreatic cancer.



On top of that, Autonomix Medical also <a href="https://www.nasdaq.com/press-release/autonomix-enters-definitive-agreement-license-intellectual-property-fda-cleared">announced a definitive agreement</a> with&nbsp;RF Innovations to license the intellectual property of its Apex 6 Radiofrequency Generator. The deal is set to be completed by the end of the month.



All of this news resulted in shares of AMIX stock rallying 130% during normal trading hours yesterday. That came with heavy trading as some 152 million shares changed hands. For the record, its daily average trading volume is about 3 million shares.



<h2>AMIX Stock Movement on Tuesday</h2>



Considering the massive rally AMIX stock saw yesterday, it makes sense it would give up some of those gains the following day. This has the stock down 16.7% as of Tuesday morning.



Trading activity this morning has more than 1.3 million shares on the move. That&rsquo;s still below the company&rsquo;s daily average trading volume.



Investors will want to stick around for more of the most recent stock market stories on Tuesday!



We have all of the hottest market happenings traders need to know about today! A few examples include what&rsquo;s happening with shares of Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>), Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) and Rumble&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rum-stock-quote/">RUM</a>) stock today. All of that news is ready at the links below!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/trade-of-the-day-buy-rumble-rum-stock-call-options-as-trump-trades-gain/">Trade of the Day: Buy Rumble (RUM) Stock Call Options as Trump Trades Gain</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-autonomix-medical-amix-stock-down-17-today/">Why Is Autonomix Medical (AMIX) Stock Down 17% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Autonomix Medical (AMIX) Stock Down 17% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Greenpro Capital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) stock is dropping on Tuesday after the financial consulting and corporate advisory services company&rsquo;s shares underwent a large rally during the prior day of trading.



This saw shares of GRNQ stock close out normal trading hours on Monday up more than 34%. That came with heavy trading as over 10 million units moved yesterday. To put that number in perspective, the daily average trading volume for Greenpro Capital shares is around 183,000.



This rally didn&rsquo;t come without any news. The catalyst behind it was Greenpro Capital announcing a new strategic partnership. This brings together Greenpro Capital, its subsidiary Green-X and Bank Islam Trust Company.



Greenpro Capital CEO Dr. CK Lee <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">said this about the strategic alliance</a>.




&ldquo;We are extremely excited to have&nbsp;Bank Islam Trust&nbsp;as our strategic partner to penetrate the Muslim and&nbsp;Middle East&nbsp;communities. There is a huge demand for digital asset investments from the&nbsp;Middle East, and we will structure our STO and RWA assets as alternative investment products to cater to their demand.&rdquo;




<h2>GRNQ Stock Movement Today</h2>



Considering the rally yesterday, it makes sense that GRNQ stock would give up some of those gains today. That has the stock falling 19.1% as of Tuesday morning. Traders will note that GRNQ shares were down 5.6% year-to-date when markets closed yesterday.



Today&rsquo;s stock market movement comes with some 230,000 shares of GRNQ on the move. That&rsquo;s already above Greenpro Capital&rsquo;s daily average trading volume.



Investors will want to keep reading for more of the biggest stock market stories on Tuesday!



We have all of the hottest stock market happenings to report on today! That includes the latest news for Autonomix Medical&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock, Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock and Silo Pharma&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock this morning. All of this info is ready to go at the links below!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-autonomix-medical-amix-stock-down-17-today/">Why Is Autonomix Medical (AMIX) Stock Down 17% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-conduit-pharmaceuticals-cdt-stock-up-73-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-silo-pharma-silo-stock-up-123-today/">Why Is Silo Pharma (SILO) Stock Up 123% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-greenpro-capital-grnq-stock-down-19-today/">Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Greenpro Capital (GRNQ) Stock Down 19% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers on Thursday morning with all of the latest news this morning!



Moving stocks on Thursday are loads of earnings reports, a public stock pricing, and exclusive license deal and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is rocketing more than 68% after announcing an <a href="https://www.nasdaq.com/press-release/conduit-pharmaceuticals-enters-exclusive-license-agreement-astrazeneca-multiple">exclusive license agreement</a>.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 49% alongside heavy pre-market trading.</li>



<li>Harrow (NASDAQ:<a href="https://investorplace.com/stock-quotes/hrow-stock-quote/">HROW</a>) stock is surging more than 39% with its <a href="https://finance.yahoo.com/news/harrow-announces-second-quarter-2024-200100329.html">latest earnings report</a>.</li>



<li>1847 Holdings (NYSEMKT:<a href="https://investorplace.com/stock-quotes/efsh-stock-quote/">EFSH</a>) shares are rising over 30% despite a lack of news this morning.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) stock is increasing more than 26% without any clear news today.</li>



<li>Coeptis Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/coep-stock-quote/">COEP</a>) shares are climbing over 24% on Thursday morning.</li>



<li>Aspen Aerogels (NYSE:<a href="https://investorplace.com/stock-quotes/aspn-stock-quote/">ASPN</a>) stock is heading close to 23% higher <a href="https://www.tipranks.com/news/company-announcements/aspen-aerogels-projects-financial-outlook-for-2024-2">with its new guidance</a>.</li>



<li>CompoSecure (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmpo-stock-quote/">CMPO</a>) shares are gaining more than 19% on <a href="https://au.finance.yahoo.com/news/composecure-inc-cmpo-q2-earnings-233506766.html">Q2 earnings and revenue beats</a>.</li>



<li>Digital Turbine (NASDAQ:<a href="https://investorplace.com/stock-quotes/apps-stock-quote/">APPS</a>) stock is jumping over 18% with its <a href="https://www.prnewswire.com/news-releases/digital-turbine-reports-fiscal-2025-first-quarter-financial-results-302217006.html">most recent earnings report</a>.</li>



<li>Klaviyo (NYSE:<a href="https://investorplace.com/stock-quotes/kvyo-stock-quote/">KVYO</a>) shares are up more than 18% <a href="https://www.businesswire.com/news/home/20240807687579/en/Klaviyo-Announces-Second-Quarter-2024-Financial-Results">after a guidance increase</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Cardlytics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdlx-stock-quote/">CDLX</a>) stock is crashing over 54% with its <a href="https://www.nasdaq.com/press-release/cardlytics-announces-second-quarter-2024-financial-results-2024-08-07">earnings report and a CEO change</a>.</li>



<li>Outset Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/om-stock-quote/">OM</a>) shares are plummeting more than 47% after <a href="https://finance.yahoo.com/news/outset-medical-inc-om-reports-223509136.html">missing Q2 revenue estimates</a>.</li>



<li>Bumble (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmbl-stock-quote/">BMBL</a>) stock is diving over 40% after <a href="https://www.reuters.com/technology/bumble-dives-revenue-forecast-cut-triggers-worries-over-turnaround-2024-08-08/">cutting its revenue guidance</a>.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are tumbling nearly 39% without any obvious news today.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) stock is taking a more than 36% beating <a href="https://www.nasdaq.com/press-release/greenlanes-vaporcom-named-usa-todays-list-americas-top-online-retail-shops-recent">following a recent rally</a>.</li>



<li>JFrog (NASDAQ:<a href="https://investorplace.com/stock-quotes/frog-stock-quote/">FROG</a>) shares are sliding over 26% on <a href="https://finance.yahoo.com/news/jfrog-nasdaq-frog-misses-q2-202336803.html">missed Q2 estimates</a>.</li>



<li>Dutch Bros (NYSE:<a href="https://investorplace.com/stock-quotes/bros-stock-quote/">BROS</a>) stock is dropping more than 21% <a href="https://seekingalpha.com/news/4136791-coffee-jolt-dutch-bros-gets-crushed-after-just-a-slight-miss-with-revenue-guidance">after missing estimates</a>.</li>



<li>Know Labs (NYSEMKT:<a href="https://investorplace.com/stock-quotes/knw-stock-quote/">KNW</a>) shares are decreasing over 21% after <a href="https://www.nasdaq.com/press-release/know-labs-inc-announces-pricing-3445-million-public-offering-2024-08-07">pricing a public offering</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) stock is falling more than 20% <a href="https://www.stocktitan.net/news/VTNR/vertex-energy-announces-second-quarter-2024-enonsrelirjb.html">with its Q2 earnings report</a>,</li>



<li>Fastly (NYSE:<a href="https://investorplace.com/stock-quotes/fsly-stock-quote/">FSLY</a>) shares close out our pre-market stock movers down over 19% <a href="https://www.investing.com/news/stock-market-news/fastly-shares-plunge-19-as-guidance-disappoints-despite-solid-q2-93CH-3560546">on a lackluster guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-8th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

AstraZeneca licensing deal boosts Conduit Pharma

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced <a href="https://www.nasdaq.com/press-release/conduit-pharmaceuticals-enters-exclusive-license-agreement-astrazeneca-multiple">an exclusive license agreement</a> with AstraZeneca&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>).



This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca. That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904.



Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical trials. Conduit Pharmaceuticals also notes that it intends to launch Phase 2 clinical trials for AZD1656 and AZD5658 this year. It intends to test their effectiveness as autoimmune disorder treatments.



Conduit Pharmaceuticals CEO Dr.&nbsp;David Tapolczay said the following about the deal.




&ldquo;The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca&rsquo;s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.&rdquo;




<h2>CDT Stock Jumps on AZN Agreement</h2>



News of this license agreement brings with it heavy trading of CDT stock. That has more than 39 million shares of AZN trading hands as of this writing. This is well above its daily average trading volume of about 3 million shares.



CDT stock is up 123.2% as of Thursday morning.



Investors will want to stick around for even more of the most recent stock market news today.



We have all of the hottest market happenings worth reading about on Thursday. That includes the biggest pre-market stock movers this morning and more. All of that info is ready to go at the links below!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-8th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Thursday</a></li>



<li><a href="https://investorplace.com/2024/08/ftnt-stock-alert-why-investors-are-piling-into-fortinet-today/">FTNT Stock Alert: Why Investors Are Piling Into Fortinet Today</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-lyft-stock-down-despite-surprise-q2-profits/">Why Is LYFT Stock Down Despite Surprise Q2 Profits?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-123-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) just reported results for the second quarter of 2024.<ul><li>Conduit Pharmaceuticals reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cdt-stock-earnings-conduit-pharmaceuticals-for-q2-of-2024/">CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!



Moving stocks this morning are earnings reports, a stock offering, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Digital Ally (NASDAQ:<a href="https://investorplace.com/stock-quotes/dgly-stock-quote/">DGLY</a>) stock is rocketing more than 107% alongside heavy pre-market trading.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are soaring over 53% with the <a href="https://www.nasdaq.com/press-release/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides">release of its Q2 earnings report</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is surging more than 42% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518494&amp;type=PDF&amp;symbol=CDT&amp;cdn=197541151657f71d6ed19abcc1e0e48e&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=3&amp;formDescription=Initial+statement+of+beneficial+ownership+of+securities&amp;dateFiled=2024-08-13">an investment update</a>.</li>



<li>Nuburu (NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) shares are rising over 26% despite a lack of news this morning.</li>



<li>Jianzhi Education Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is gaining close to 19% even with a <a href="https://www.nasdaq.com/press-release/jianzhi-education-technology-group-company-limited-receives-nasdaq-notification-0">recent delisting notice</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are increasing more than 18% on <a href="https://www.nasdaq.com/press-release/edible-garden-reports-157-increase-gross-profit-fueled-year-over-year-growth-61-cut">strong Q2 earnings</a>.</li>



<li>Ucloudlink (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucl-stock-quote/">UCL</a>) stock is heading over 16% higher with its <a href="https://www.nasdaq.com/press-release/ucloudlink-group-inc-announces-unaudited-second-quarter-2024-financial-results-2024">most recent earnings report</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) shares are jumping 16% with strong early morning trading.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is climbing more than 15% with its <a href="https://www.stocktitan.net/news/SERV/serve-robotics-announces-second-quarter-2024-wqwtqr037uv4.html">Q2 earnings report</a>.</li>



<li>Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) shares are up over 15% after posting <a href="https://www.nasdaq.com/press-release/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-year-over">positive Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is crashing more than 42% after <a href="https://www.nasdaq.com/press-release/tc-biopharm-announces-pricing-20-registered-direct-offering-2024-08-13">pricing a registered direct offering</a>.</li>



<li>Surgepays (NASDAQ:<a href="https://investorplace.com/stock-quotes/surg-stock-quote/">SURG</a>) shares are plummeting over 26% after <a href="https://www.prnewswire.com/news-releases/surgepays-announces-second-quarter-2024-financial-results-302221503.html">reporting a Q2 loss</a>.</li>



<li>Arcadia Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rkda-stock-quote/">RKDA</a>) stock is diving more than 16% after <a href="https://markets.businessinsider.com/news/stocks/rkda-stock-earnings-arcadia-biosciences-for-q2-of-2024-1033684150">missing Q2 EPS estimates</a>.</li>



<li>Ouster (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/">OUST</a>) shares are taking an over 16% beating on <a href="https://www.businesswire.com/news/home/20240813944318/en/Ouster-Reports-Strong-Revenue-and-Margins-for-Second-Quarter-2024">mixed Q2 earnings</a>.</li>



<li>QuickLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/quik-stock-quote/">QUIK</a>) stock is tumbling more than 16% with its <a href="https://www.prnewswire.com/news-releases/quicklogic-reports-41-year-over-year-revenue-growth-for-second-quarter-fiscal-2024-302221555.html">latest earnings release</a>.</li>



<li>Brinker International (NYSE:<a href="https://investorplace.com/stock-quotes/eat-stock-quote/">EAT</a>) shares are sliding over 16% after <a href="https://www.investing.com/news/stock-market-news/brinker-international-stock-tumbles-13-on-q4-earnings-miss-93CH-3570960">posting an earnings miss</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is falling more than 15% after <a href="https://www.stocktitan.net/news/PRTG/portage-biotech-announces-1-for-20-reverse-stock-sficaewojjpr.html">announcing a reverse stock split</a>.</li>



<li>Global E Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/glbe-stock-quote/">GLBE</a>) shares are decreasing over 14% with its <a href="https://www.stocktitan.net/news/GLBE/global-e-reports-second-quarter-2024-1dq5hcfetvn1.html">Q2 earnings report</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 14% without any clear news this morning.</li>



<li>WISeKey (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkey-stock-quote/">WKEY</a>) shares close out our pre-market stock movers down nearly 14% on a <a href="https://www.nasdaq.com/press-release/sealcoin-secures-50-million-investment-commitment-gem-digital-limited-through-0">new investment</a> <a href="https://www.nasdaq.com/press-release/wisekey-partners-venafi-post-quantum-encryption-services-2024-08-14">and partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is up on Wednesday following a shareholder update concerning a major investor in the company.



New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518480&amp;type=PDF&amp;symbol=CDT&amp;cdn=ab0223c3ed6ed1bb801100f67e0b2323&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-08-13">holds a 14.8% stake in CDT stock</a>. This comes from the 12.5 million shares off CDT that the company owns, as well as warrants for another 2 million shares.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals is based on the company&rsquo;s outstanding shares of CDT stock. That was sitting at 98,004,699 shares at the time of this writing.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals comes from a Senior Secured Promissory Note issued earlier this month. This was part of Conduit Pharmaceuticals&rsquo; merger agreement with Murphy Canyon Acquisition Corp.



<h2>CDT Stock Movement on Wednesday</h2>



Following this news, shares of CDT stock are seeing heavy trading today. This has more than 72 million units changing hands as of this writing. That&rsquo;s a massive increase compared to the company&rsquo;s daily average trading volume of about 10 million shares.



CDT stock is up 11.7% as of Wednesday morning. Even so, the clinical-stage specialty biopharmaceutical company&rsquo;s shares are still down 96.7% since the start of the year.



Investors will want to stick around for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market news ready to go today! Among that is what has shares of Intuitive Machines&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lunr-stock-quote/">LUNR</a>), Nuburu&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) and Clover Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) stock on the move today. You can catch up on all of this at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/trade-of-the-day-explore-the-final-frontier-with-intuitive-machines-lunr-stock/">Trade of the Day: Explore the Final Frontier with Intuitive Machines (LUNR) Stock</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-nuburu-buru-stock-up-47-today/">Why Is Nuburu (BURU) Stock Up 47% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/clov-stock-alert-what-to-know-about-clover-healths-big-insider-buy/">CLOV Stock Alert: What to Know About Clover Health&rsquo;s Big Insider Buy</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-12-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?

AEON

AMIX

APPS

ASPN

BMBL

BMRA

BNOX

BROS

BURU

CDLX

CMPO

COEP

DGLY

EDBL

EFSH

FROG

FSLY

GLBE

GNLN

GRNQ

HROW

KMDA

KVYO

LTRY

LUXH

LXEH

MICS

OUST

PASG

PRTG

QUIK

RKDA

SERV

SILO

SISI

SPRC

SURG

TANH

TCBP

VIRX

VNCE

VTNR

WENA

WKEY

Press Releases

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

Management

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

General

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

Conduit Pharmaceuticals to Join Russell 3000® Index

Health Care

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SQFT

SQFTP

SQFTW

Akoya Biosciences

Applied DNA Sciences, Inc. - Common Stock

Applied DNA Sciences

Bionano Genomics

Codexis

Champions Oncology

Genetic Technologies Ltd - American Depositary Shares

Genetic Technologies

Harvard Bioscience

Lifecore Biomedical

Inotiv

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Sys

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

Cable Design

Conduit Pharmaceuticals shares are trading higher after AstraZeneca reported a 9.9% stake in the company.

Comments

Conduit Pharmaceuticals

Intérêt court

Conduit Pharmaceuticals (NASDAQ:CDT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL